Strategy for randomised clinical trials in rare cancers
Abstract
Problems of small trials Randomised controlled trials are regarded as the standard when comparing a new treatment with the standard treatment for a particular cancer. However, to be considered clinically worth while in clinical trials, these (essentially) very toxic regimens typically need to show relative reductions in the risk of death of 20-30%. For studies to have sufficient statistical power (≥80%) to detect treatment effects of this magnitude, several hundreds of deaths (typically 200 to 500) need to be observed. This implies trial sizes that are unrealistically large for rare cancers. Furthermore, even if a much larger treatment effect could be expected, estimates derived from the resulting (small) randomised controlled trial would lack the precision needed for clinical decisions. Thus, investigators who wish to test new treatments for rare cancers tend to conduct either single arm studies of tumour response rates or comparative studies using historical controls. Alternatively, investigators may attempt to conduct small, underpowered, randomised controlled trials. These give rise to estimates of outcome that have unacceptably large confidence intervals and thus fail to provide clear answers. On these grounds, protocol review boards may regard such trials as unethical.2 However, some have argued that in situations such as rare diseases, small randomised trials are the “only way that any unbiased measurements of effectiveness can be made.”3 Summary points Treatments for rare cancers are difficult to evaluate in randomised trials as there are too few patients to detect any genuine treatment differences Combination of previous data with trial data by bayesian techniques could help overcome this problem Data from related studies are scored and weighted according to pertinence, validity, and precision The method of combining data increases the robustness of information from small trials and can be used to help design and provide justification for such trials One suggested solution to the problem is to use bayesian statistical approaches.4 These involve quantifying the information available about the outcome of interest in the form of a prior probability distribution at the design stage and combining this with the trial data to give a posterior distribution. Conclusions are then drawn from the posterior distribution. The key step in a bayesian approach is summarising the information available before the trial. This will often be from single arm studies or studies of response rate rather than survival. Footnotes A paper giving a worked example of the method is available on bmj.com Contributors KBGD, PB, and DM first considered and discussed the small trials problem. SBT and DM proposed the use of a bayesian approach and then outlined the initial approach to be taken. All authors contributed to the subsequent development of the methodology and the writing of the paper. Funding SBT is funded by the National Medical Research Council of Singapore Competing interests None declared.Keywords
This publication has 18 references indexed in Scilit:
- Elicitation of prior distributions for a phase III randomized controlled trial of adjuvant therapy with surgery for hepatocellular carcinomaControlled Clinical Trials, 2003
- Following a Trial That Stopped Early: What Next for Adjuvant Hepatic Intra-Arterial Iodine-131 Lipiodol in Resectable Hepatocellular Carcinoma?Journal of Clinical Oncology, 2002
- Underpowered studiesBritish Journal of Surgery, 2002
- Monitoring of large randomised clinical trials: a new approach with Bayesian methodsThe Lancet, 2001
- Methods in health service research: An introduction to bayesian methods in health technology assessmentBMJ, 1999
- Surrogate End Points in Clinical Trials: Are We Being Misled?Annals of Internal Medicine, 1996
- Assessing the quality of reports of randomized clinical trials: Is blinding necessary?Controlled Clinical Trials, 1996
- Clinical trials and rare diseases: a way out of a conundrumBMJ, 1995
- Over-the-counter cold medications. A critical review of clinical trials between 1950 and 1991JAMA, 1993
- Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examplesBritish Journal of Cancer, 1977